We’ve renewed the UCL–Eisai partnership for another 5 years (to 2030), accelerating treatments for neurodegenerative diseases incl. Alzheimer’s, Parkinson’s & ALS. Proud to support translational research from lab to patient. Read more: tinyurl.com/4tua9kxr

We are celebrating 75 years of research, innovation and education with global patient impact! Watch how Queen Square’s unique combination of research, clinical care and collaboration has shaped major neurological breakthroughs and continues to drive future treatments youtu.be/QbgSKrvgQXw

A huge thank you to everyone who came along and helped make Social Night such a fun evening. Special shout-out to @davemomi.bsky.social and @claraweber.bsky.social for organising the event! Here’s to the conversations and connections that make OHBM special!

Excited to be here at #OHBM2026! 🧠 Come and chat with me about our recent paper on DTI-ALPS in LBD, at poster 0203 on Monday and Tuesday! Looking forward to connecting with new and old faces

Pleased to share our new paper in Alzheimer’s Research and Therapy, as part of the collection on Advances in LBD research! We found that DTI-ALPS was reduced in DLB and PDD relative to PD and controls. DTI-ALPS was also further reduced for DLB versus PD link.springer.com/article/10.1... (1/3)

Join the LBD PIA ISTAART Journal Club on 29 April, 5pm London time. Hear from authors on biomarkers and survival in Lewy body dementia, with live Q and A. Don’t miss it. www.dementiaresearcher.nihr.ac.uk/event/lbd-pi...

Really excited to share first published paper of the year! Thank you to @uclbrainscience.bsky.social for highlighting: www.ucl.ac.uk/brain-scienc.... We found different organisational changes in Lewy body disease patients with dementia versus those with intact cognition, using structural gradients.

Great to see this published @movedisorder.bsky.social movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...: We found that DTI-ALPS (a proposed indirect proxy for glymphatic clearance) is lower in Parkinson's patients who progress to poor cognitive outcomes, and correlates with cognition. 1/2

Join Dr Angeliki Zarkali’s team at UCL Dementia Research Centre to support neuroimaging and clinical research into Parkinson’s and Lewy Body Dementia. Closing date: 10th July www.dementiaresearcher.nihr.ac.uk/job/research...

Pleased to share our new work. Black communities face higher Parkinson’s disease burden, but we know they remain underrepresented in research. We highlight the key barriers - distrust, stigma, and accessibility - and offer community-driven recommendations to increasing research engagement.

Really pleased to share our new paper in @alzdemjournals.bsky.social. We compared plasma biomarkers and diffusion MRI between DLB, PDD and PD – to our knowledge this is the first report of plasma p-tau217 concentrations in LBD and PD! dx.doi.org/10.1002/alz....

The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson’s disease go.nature.com/44TCQ6u

Thank you so much to @braincomms.bsky.social for highlighting our work! TLDR: white matter maters - do read the paper for more! And thank you to all amazing co-authors without whom this project would not have been possible (amongst them on bluesky: @naomihannaway.bsky.social @rimonaweil.bsky.social)

🧠 130 people now in this UK Dementia Starter Pack! 🧠 📈 (50 more than 2 days ago!) 📈 A great mix of Profs/PIs/Post-docs/PhDs/Technicians. Please re-post so it can reach a wider audience as I'm sure there are more of us out there ☺️🦋 go.bsky.app/S6FfsTp